Efficacy And SafetyAdditional positive data shows significant improvement in patients treated twice daily with QRX003, supporting its efficacy in treating Netherton Syndrome.

Market PotentialAn approved therapy for NS has significant market potential as NS still remains a very difficult to treat disease with no approved disease-modifying therapeutic options.

Safety ProfileThe absence of new safety concerns despite increased dosing of QRX003 positively supports its safety profile.

Bears Say

Investor ConcernsThe shares are trading down approximately 25% as some investors may be concerned that QRX003 did not maintain symptom relief durability or 'cure' patients.

Symptom ReliefUpdated data showed that 4 weeks post-discontinuation of therapy, the patients’ symptom and disease severity scores returned essentially to baseline levels.

Therapy RequirementDiscontinuation of QRX003 treatment reverses the treatment benefit, suggesting potential chronic use may be required for patients to maintain symptom relief.

Financials

Income Statement >

Options Prices

Currently, No data available

---

Ownership Overview

17.79% Insiders

―

Mutual Funds

15.24% Other Institutional Investors

66.96% Public Companies and

Individual Investors

Detailed Ownership Overview >

QNRX FAQ

What was Quoin Pharmaceuticals Ltd’s price range in the past 12 months?

Quoin Pharmaceuticals Ltd lowest stock price was $5.01 and its highest was $54.95 in the past 12 months.

What is Quoin Pharmaceuticals Ltd’s market cap?

Quoin Pharmaceuticals Ltd’s market cap is $5.45M.

When is Quoin Pharmaceuticals Ltd’s upcoming earnings report date?

Quoin Pharmaceuticals Ltd’s upcoming earnings report date is Aug 14, 2025 which is in 46 days.

How were Quoin Pharmaceuticals Ltd’s earnings last quarter?

Quoin Pharmaceuticals Ltd released its earnings results on May 13, 2025. The company reported -$6.5 earnings per share for the quarter, beating the consensus estimate of -$7.175 by $0.675.

Is Quoin Pharmaceuticals Ltd overvalued?

According to Wall Street analysts Quoin Pharmaceuticals Ltd’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Quoin Pharmaceuticals Ltd pay dividends?

Quoin Pharmaceuticals Ltd does not currently pay dividends.

What is Quoin Pharmaceuticals Ltd’s EPS estimate?

Quoin Pharmaceuticals Ltd’s EPS estimate is -6.83.

How many shares outstanding does Quoin Pharmaceuticals Ltd have?

Quoin Pharmaceuticals Ltd has 588,167 shares outstanding.

What happened to Quoin Pharmaceuticals Ltd’s price movement after its last earnings report?

Quoin Pharmaceuticals Ltd reported an EPS of -$6.5 in its last earnings report, beating expectations of -$7.175. Following the earnings report the stock price went up 3.922%.

Which hedge fund is a major shareholder of Quoin Pharmaceuticals Ltd?

Currently, no hedge funds are holding shares in QNRX

Company Description

Quoin Pharmaceuticals Ltd

Quoin Pharmaceuticals (QNRX) is a biopharmaceutical company focused on developing and commercializing innovative therapeutic products. The company operates primarily in the pharmaceutical sector, aiming to address unmet medical needs in rare and orphan diseases. Quoin Pharmaceuticals is dedicated to advancing its pipeline of products through rigorous research and development efforts to bring new treatment options to patients around the world.